biostudies-literatureUnknown13Brandon RMaurice Wilkins Centre for Molecular BiodiscoveryHealth Research Council of New Zealand<h4>Background</h4>Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine.<h4>Aims</h4>We hypothesized that people with type 2 diabetes who generally have high insulin resistance, such as people of Māori/Pacific ethnicity, and those with obesity and/or hypertriglyceridemia (OHTG), would have greater glucose-lowering by pioglitazone (an insulin sensitizer) versus vildagliptin (an insulin secretagogue).<h4>Methods</h4>A randomised, open-label, two-period crossover trial was conducted in New Zealand. Adults with type 2 diabetes, HbA1c>58mmol/mol (>7.5%), received 16 weeks of either pioglitazone (30mg) or vildagliptin (50mg) dailFrontiers in endocrinology1091421https://www.ebi.ac.uk/biostudies/studies/S-EPMC9869378biostudies-literatureStratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.PMC9869378Merry TSmallman KShepherd PRNehren NTweedie-Cullen RBrandon RKing FPaul RMerriman TRJiang YDoran RJOrr-Walker BYeu RQMacaskill-Smith KAHindmarsh JHMoffitt ADoherty GClark PLeask MPMurphy RfalseStratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial.<h4>Background</h4>Understanding which group of patients with type 2 diabetes will have the most glucose lowering response to certain medications (which target different aspects of glucose metabolism) is the first step in precision medicine.<h4>Aims</h4>We hypothesized that people with type 2 diabetes who generally have high insulin resistance, such as people of Māori/Pacific ethnicity, and those with obesity and/or hypertriglyceridemia (OHTG), would have greater glucose-lowering by pioglitazone (an insulin sensitizer) versus vildagliptin (an insulin secretagogue).<h4>Methods</h4>A randomised, open-label, two-period crossover trial was conducted in New Zealand. Adults with type 2 diabetes, HbA1c>58mmol/mol (>7.5%), received 16 weeks of either pioglitazone (30mg) or vildagliptin (50mg) dail2022-01-01T00:00:00Z20222026-05-28T03:41:12.85Z2025-04-05T21:07:37.168ZS-EPMC98693783669903910.3389/fendo.2022.1091421